Agreement enables AbbVie to leverage ConcertAI-Caris’ extensive clinical and genomic database, coupled with Artificial Intelligence and Machine Learning (AI/ML)-derived insights to accelerate drug discovery, clinical development and precision medicine efforts in oncology
Cambridge, Ma, and Dallas, Tx., Jan. 9, 2024 /PRNewswire/ — ConcertAI, and Caris Life Sciences announced a multi-year partnership to support AbbVie’s precision medicine-driven research and development efforts, and clinical trial optimization in oncology.
The agreement will allow AbbVie to leverage Caris’ expansive real-world clinico-genomic database in oncology and ConcertAI’s collection of research-grade clinical data across a wide range of cancers, to guide the development of novel therapies for patients most likely to benefit. The agreement will also allow AbbVie to utilize ConcertAI and Caris’ clinical network and laboratory capabilities combined with artificial intelligence/machine learning to optimize oncology clinical trials and patient enrollment.
“We are continuing to expand our drug discovery and development efforts in oncology, with the ultimate goal to deliver transformative treatments to cancer patients,” said Tom Hudson, SVP, Chief Scientific Officer, Global Research at AbbVie. “This agreement marks a key step in that direction, as it represents a union of cutting-edge technology and pioneering science, leveraging the power of big data, artificial intelligence and machine learning to propel our efforts in the fight against cancer.”
“This partnership furthers our goals of enabling causal biological inferences, where multi-modal data can be integrated with AI/ML-based approaches in drug discovery, translation and development, to accelerate oncology pipelines, and allow our biopharma partners to discover and deliver better medicines faster,” said Jeff Elton, Ph.D., CEO of ConcertAI.
“We are thrilled to work with AbbVie, a leader in driving innovation in drug development, to support their work in oncology,” Said George Sledge, MD FASCO, Chief Medical Officer of Caris, “I think this work may help identify novel targets and mechanisms, and key levers to drive clinical trial excellence to support AbbVie’s oncology portfolio.”
About ConcertAI:
ConcertAI is the leader in Real-World Evidence (RWE) and Generative AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies. Serving over 1,900 clinical sites and 45 biomedical innovators ConcertAI companies and solutions are Best in KLAS and awarded the 2020, 2021, and 2022 KLAS recognition. Headquartered in Cambridge, MA, ConcertAI has offices in Philadelphia, Frankfurt, Raleigh-Durham, and Tokyo. For more information, visit us at www.concertai.com.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the pioneer in precision medicine and leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This convergence of data and machine learning provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. The company’s latest advancement, Caris Assure™, is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) – making it the most powerful liquid biopsy assay ever developed.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributors provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on LinkedIn.